These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9471862)

  • 1. [Analysis of a series of radical prostatectomies].
    Rioja Sanz LA; Liedana Torres JM; Roncales Badal A; Gil Sanz MJ; Villanueva Benedicto A; Rodríguez Vela L; Gil Martínez P
    Actas Urol Esp; 1997 Oct; 21(9):809-16. PubMed ID: 9471862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Positive margins. Surgical techniques and progression after radical prostatectomy].
    Gil Sanz MJ; Elena P; Borque Fernando A; Bono Ariño A; García Julián G; Rioja Sanz LA
    Actas Urol Esp; 1997 Oct; 21(9):898-902. PubMed ID: 9471873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
    Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
    Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radical prostatectomy in cancer of the prostate. Our experience apropos of 55 cases with 3-year follow-up].
    Leandri P; Rossignol G; Caissel J
    Ann Urol (Paris); 1986; 20(6):419-21. PubMed ID: 3566199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predicting factors of tumor organ-confinement in adenocarcinoma of the prostate].
    Borque Fernando A; Allepuz Losa C; Del Agua Arias C; Valdivia Navarro P; Ascaso Cornago I; Rioja Sanz LA
    Actas Urol Esp; 1997 Oct; 21(9):890-7. PubMed ID: 9471872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical results of radical prostatectomy for patients with prostate cancer in Macau.
    Ho SF; Lao HF; Li K; Tse MK
    Chin Med J (Engl); 2008 Feb; 121(4):295-8. PubMed ID: 18304459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary results in a series of patients with prostate cancer who underwent radical prostatectomy].
    Chiva Robles V; Luján Galán M; Páez Borda A; Santos Arrontes D; Espinales Castro G; Berenguer Sánchez A
    Arch Esp Urol; 2004 Mar; 57(2):111-8. PubMed ID: 15074779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radical prostatectomy. The surgical complications].
    Martín-Marquina Aspiunza A; Zudaire Bergera JJ; Sánchez Zalabardo D; Arocena García-Tapia J; Sanz Pérez G; Díez-Caballero Alonso F; Rosell Costa D; Robles García JE; Berián Polo JM
    Actas Urol Esp; 1999 Jan; 23(1):5-9. PubMed ID: 10089626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
    Smith JA; Chan RC; Chang SS; Herrell SD; Clark PE; Baumgartner R; Cookson MS
    J Urol; 2007 Dec; 178(6):2385-9; discussion 2389-90. PubMed ID: 17936849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.